Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Safe delivery of therapeutic genes into specific chromosomal sites using engineered retroviral integrase

Safe delivery of therapeutic genes into specific chromosomal sites using engineered retroviral... Gene Therapy and Regulation , Vol. 2, No. 4, pp. 369 – 387 (2004)  VSP 2004. Also available online - www.vsppub.com Safe delivery of therapeutic genes into specific chromosomal sites using engineered retroviral integrase ∗ THOMAS A. WILKINSON, WENJIE TAN and SAMSON A. CHOW † Department of Molecular and Medical Pharmacology, Molecular Biology Institute, and UCLA AIDS Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA Received 16 March 2005; revised 31 March 2005 Abstract —Gene therapy approaches that involve the permanent insertion of therapeutic genes into host chromosomal DNA have many desirable features and show considerable promise for success in the clinic. One major drawback of these approaches is that any unintended insertion events from the therapy can potentially have detrimental effects in patients, as demonstrated by the development of malignancies in both animal and human studies. Therefore, directing the integration of foreign genes into “safe sites” within the genome is highly desirable for these approaches. In retroviral-based vector systems, the viral enzyme integrase (IN) catalyzes the insertion of a desired transgene nonspecifically into the host cell genome. Efforts to engineer IN to recognize specific target DNA sequences within the genome, and thereby improve the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Gene Therapy and Regulation Brill

Safe delivery of therapeutic genes into specific chromosomal sites using engineered retroviral integrase

Download PDF
19 pages

Loading next page...
 
/lp/brill/safe-delivery-of-therapeutic-genes-into-specific-chromosomal-sites-0CGPZSYKHe

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Brill
Copyright
© 2004 Koninklijke Brill NV, Leiden, The Netherlands
ISSN
1388-9532
eISSN
1568-5586
DOI
10.1163/1568558043967490
Publisher site
See Article on Publisher Site

Abstract

Gene Therapy and Regulation , Vol. 2, No. 4, pp. 369 – 387 (2004)  VSP 2004. Also available online - www.vsppub.com Safe delivery of therapeutic genes into specific chromosomal sites using engineered retroviral integrase ∗ THOMAS A. WILKINSON, WENJIE TAN and SAMSON A. CHOW † Department of Molecular and Medical Pharmacology, Molecular Biology Institute, and UCLA AIDS Institute, UCLA School of Medicine, Los Angeles, CA 90095, USA Received 16 March 2005; revised 31 March 2005 Abstract —Gene therapy approaches that involve the permanent insertion of therapeutic genes into host chromosomal DNA have many desirable features and show considerable promise for success in the clinic. One major drawback of these approaches is that any unintended insertion events from the therapy can potentially have detrimental effects in patients, as demonstrated by the development of malignancies in both animal and human studies. Therefore, directing the integration of foreign genes into “safe sites” within the genome is highly desirable for these approaches. In retroviral-based vector systems, the viral enzyme integrase (IN) catalyzes the insertion of a desired transgene nonspecifically into the host cell genome. Efforts to engineer IN to recognize specific target DNA sequences within the genome, and thereby improve the

Journal

Gene Therapy and Regulation – Brill

Published: Jan 1, 2004

Keywords: ZINC-FINGER PROTEIN; INTEGRASE; SITE-SPECIFIC INTEGRATION; HUMAN IMMUNODEFICIENCY VIRUS; GENE THERAPY

There are no references for this article.